|1.||Balasegaram, Manica: 5 articles (01/2012 - 10/2006)|
|2.||Yi, Taolin: 5 articles (12/2011 - 11/2002)|
|3.||Rijal, S: 5 articles (03/2010 - 05/2003)|
|4.||Wyllie, Susan: 4 articles (02/2015 - 09/2004)|
|5.||Sundar, Shyam: 4 articles (02/2015 - 06/2005)|
|6.||Koirala, S: 4 articles (03/2010 - 05/2003)|
|7.||Singh, R: 4 articles (03/2010 - 01/2000)|
|8.||Chappuis, F: 4 articles (03/2010 - 05/2003)|
|9.||Ritmeijer, Koert: 4 articles (07/2007 - 08/2006)|
|10.||Aronson, Naomi E: 3 articles (10/2015 - 04/2006)|
|1.||Visceral Leishmaniasis (Kala Azar)
04/01/2007 - "In most of the Indian subcontinent, the first line treatment for visceral leishmaniasis (VL) is sodium stibogluconate (SSG), an antimonial drug, but the efficacy of the drug varies according to region. "
06/01/1996 - "The implementation of action plan not only established declining trends in morbidity and mortality due to Visceral Leishmaniasis in the district but also successfully contained the cases unresponsive to first line treatment with Sodium Stibogluconate by reducing the prevalence of such cases from 12.42% in 1992 to 8.59% in 1994. "
03/01/1998 - "Results of the study show that treatment of cases of Kala-azar with sodium stibogluconate in a dosage of 20 mg/kg/day for a longer period of 30 days is effective with a higher cure rate and minimum side effects, for treatment of cases of Kala-azar in this eastern part of Nepal, endemic for the disease."
01/01/1977 - "At low concentrations, sodium stibogluconate, the drug of choice for kala azar treatment in Iraq proved to be poorly effective in the prevention of promastigotes growth in vitro. "
06/01/2001 - "The aim of this study was to evaluate the efficacy of a 20 days regimen of sodium stibogluconate and to ascertain the epidemiological, clinical and laboratory features of visceral leishmaniasis in children. "
07/04/1987 - "Safety and efficacy of high-dose sodium stibogluconate therapy of American cutaneous leishmaniasis."
01/01/1983 - "We conclude that this high dose sodium stibogluconate regimen is safe and effective for treating cutaneous leishmaniasis caused by L. "
07/01/1988 - "We recommend intralesional Pentostam as a safe and effective method of treating acute cutaneous leishmaniasis."
10/01/2010 - "Efficacy of short-duration (twice weekly) intralesional sodium stibogluconate in treatment of cutaneous Leishmaniasis in India."
07/01/2007 - "Comparative efficacy of intralesional sodium stibogluconate (SSG) alone and its combination with intramuscular SSG to treat localized cutaneous leishmaniasis: Results of a pilot study."
07/01/1994 - "Sodium stibogluconate is the mainstay of treatment for all forms of leishmaniasis. "
12/01/1998 - "Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent U.S. "
03/01/2011 - "Leishmaniasis of the lip diagnosed by lymph node aspiration and treated with a combination of oral ketaconazole and intralesional sodium stibogluconate."
10/28/2010 - "A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis."
11/01/2008 - "Furthermore, a field isolate of Leishmania donovani resistant to sodium stibogluconate (SbV), one of the drugs most commonly used to treat leishmaniasis, is equally susceptible to the tested PIs compared with a sensitive strain, thus suggesting that resistance to SbV does not result in cross-resistance to PIs. "
05/01/2000 - "He was successfully cleared of the infection by the administration of sodium stibogluconate, with no deterioration of renal function or other complications."
06/01/1989 - "Therefore in the present study, the effect of LK on infected macrophages from BALB/c mice following specific infection and subsequent treatment with sodium stibogluconate has been investigated. "
01/01/2015 - "Cationic liposomal sodium stibogluconate (SSG), a potent therapeutic tool for treatment of infection by SSG-sensitive and -resistant Leishmania donovani."
04/01/2014 - "This treatment regimen resulted in good control of VL and HIV-1 infection, while the conventional protocol of sodium stibogluconate treatment was not able to prevent multiple VL relapses. "
01/01/2010 - "major infection were randomized to receive intravenous sodium stibogluconate (SSG) 20mg/kg/day for ten doses or localized ThermoMed (TM) device heat treatment (applied at 50 degrees C for 30 seconds) in one session. "
02/01/2012 - "Intravenous sodium stibogluconate (SbV) is the mainstay of treatment for mucocutaneous leishmaniasis. "
04/01/2013 - "For patients at risk for progression to mucocutaneous leishmaniasis, first-line treatment in the United States entails the use of sodium stibogluconate (SSG), which is obtained from the Centers for Disease Control and Prevention (CDC) under an investigational drug protocol. "
04/01/2010 - "The clinical picture, plus the pathologic findings, and the response to sodium stibogluconate confirmed mucocutaneous leishmaniasis. "
12/09/2006 - "The patient was treated for mucocutaneous leishmaniasis by a 28-day course of intravenous sodium-stibogluconate therapy. "
04/01/2010 - "A 64-year-old man presented with a destructive ulceration of the central face of 23 years' duration, who was diagnosed to have mucocutaneous leishmaniasis, and showed dramatic response to intramuscular injections of sodium stibogluconate. "
|1.||Antimony Sodium Gluconate (Sodium, Stibogluconate)
|2.||Paromomycin (Paromomycin Sulfate)
|4.||Amphotericin B (Amphotericin)
|6.||Interferon-gamma (Interferon, gamma)
|9.||liposomal amphotericin B
|1.||Cryotherapy (Therapy, Cold)
|2.||Drug Therapy (Chemotherapy)